Selective effect of imatinib on serum IgM in a patient with CML.
Nagasawa
Masayuki
M
Mizutani
Shuki
S
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007075:Immunoglobulin M / Q000097:blood*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D001549:Benzamides; D007075:Immunoglobulin M; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate